中下段胸段食管鳞癌食管切除术中隆突下淋巴结清扫的预后意义
该回顾性研究纳入1587例2008至2014年于河北医科大学第四医院行根治性切除的中下段胸段食管鳞癌患者,其中非隆突下淋巴结清扫组204例、清扫组1383例,采用IPTW调整混杂因素后分析生存。结果显示隆突下淋巴结转移率9.8%,转移与病理T分期和N分期相关(P<0.001);转移者5年总生存率7.0%显著低于未转移者49.0%。隆突下淋巴结清扫可改善T3-T4a期患者长期生存,但对T1-T2期无显著获益。
要点
- 隆突下淋巴结转移率9.8%,转移者5年总生存率仅7.0%,显著劣于未转移者49.0%。
- 隆突下淋巴结转移与病理T分期、N分期显著相关(均P<0.001)。
- 隆突下淋巴结清扫改善T3-T4a期患者长期生存,T1-T2期无显著获益。
核心结论
- 隆突下淋巴结转移率虽低,但一旦转移显著恶化预后。
- 隆突下淋巴结清扫对病理T1-T2期患者长期生存无显著改善,对T3-T4a期可能带来生存获益,支持个体化手术决策。
研究设计与样本
- 单中心回顾性研究,纳入2008至2014年河北医科大学第四医院1587例中下段胸段食管鳞癌根治性切除患者。
- 非隆突下淋巴结清扫组204例,清扫组1383例,采用逆概率治疗加权(IPTW)调整混杂因素。
- 使用Kaplan-Meier曲线、log-rank检验和Cox回归进行生存分析,分析软件为R。
主要发现
- 隆突下淋巴结转移见于9.8%的患者。
- 影响隆突下淋巴结转移的因素包括病理T分期(P<0.001)和N分期(P<0.001)。
- 隆突下淋巴结转移显著影响总生存,转移者5年生存率7.0%,未转移者49.0%。
- 隆突下淋巴结清扫改善T3-T4a期患者长期生存,但对T1-T2期患者无改善。
临床怎么用
- 对病理T3-T4a期中下段胸段食管鳞癌,可考虑行隆突下淋巴结清扫以潜在改善长期生存。
- 对病理T1-T2期患者,隆突下淋巴结清扫的生存获益不显著,应个体化决策。
局限性
- 回顾性单中心设计,非随机分组,尽管采用IPTW调整混杂因素仍可能存在残余偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This retrospective study assesses the prognostic value of subcarinal lymph node dissection (SCLND) in esophageal squamous cell carcinoma (ESCC) of the middle and lower thoracic regions. METHODS: The study, conducted at the Fourth Hospital of Hebei Medical University, included 1587 patients with ESCC who underwent radical resection from 2008 to 2014, comprising 204 patients in the non-SCLND group and 1383 patients in the SCLND group. After applying inverse probability of treatment weighting (IPTW) to adjust for confounders, Kaplan-Meier curves, log-rank tests, and Cox regression were used for survival analysis, performed using R. RESULTS: SCLN metastasis was found in 9.8% of patients. Factors influencing metastasis included pathologic T stage (P < 0.001) and N stage (P < 0.001). SCLN metastasis significantly affected overall survival, with 5-year rates of 49.0% for non-metastatic versus 7.0% for metastatic patients. SCLND improved long-term survival for T3-T4a stage patients but not for T1-T2. CONCLUSIONS: Despite a low SCLN metastasis rate, its presence significantly worsens prognosis. SCLND does not significantly improve long-term survival in patients with pathologic T1-T2 tumors, but it may confer a survival benefit in T3-T4a stage disease, supporting individualized surgical decisions regarding lymph node dissection.
引用
- Xu SW, Liu JF, Rong Y, et al. The prognostic significance of subcarinal lymph node dissection in esophagectomy for middle and lower thoracic squamous cell carcinoma. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40991321. doi:10.1093/icvts/ivaf219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。